OrthoPediatrics Corp. Files 8-K for Financial Reporting
Ticker: KIDS · Form: 8-K · Filed: Mar 6, 2024 · CIK: 1425450
| Field | Detail |
|---|---|
| Company | Orthopediatrics Corp (KIDS) |
| Form Type | 8-K |
| Filed Date | Mar 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00025 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K
Related Tickers: KIDS
TL;DR
OrthoPediatrics (KIDS) filed an 8-K on March 6, 2024, updating on financial results.
AI Summary
OrthoPediatrics Corp. filed an 8-K on March 6, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing pertains to the company's ongoing business operations and financial reporting requirements.
Why It Matters
This filing provides an update on OrthoPediatrics Corp.'s financial performance and condition, which is crucial information for investors and stakeholders to assess the company's health and prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any unusual risks or events.
Key Players & Entities
- OrthoPediatrics Corp. (company) — Registrant
- KIDS (company) — Trading Symbol
- Nasdaq (company) — Exchange
- March 6, 2024 (date) — Filing Date
FAQ
What is the primary purpose of this 8-K filing for OrthoPediatrics Corp.?
The primary purpose of this 8-K filing is to report on OrthoPediatrics Corp.'s results of operations and financial condition, and to file financial statements and exhibits.
When was this 8-K filing submitted?
This 8-K filing was submitted on March 6, 2024.
What is the trading symbol for OrthoPediatrics Corp. common stock?
The trading symbol for OrthoPediatrics Corp. common stock is KIDS.
On which exchange is OrthoPediatrics Corp. common stock listed?
OrthoPediatrics Corp. common stock is listed on the Nasdaq exchange.
What is the principal executive office address for OrthoPediatrics Corp.?
The principal executive office address for OrthoPediatrics Corp. is 2850 Frontier Drive, Warsaw, Indiana 46582.
Filing Stats: 539 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-03-06 16:34:44
Key Financial Figures
- $0.00025 — ange on which registered Common Stock, $0.00025 par value per share KIDS Nasdaq Global
Filing Documents
- kids-20240306.htm (8-K) — 27KB
- kidsq42023earningsrelease.htm (EX-99.1) — 237KB
- footera.jpg (GRAPHIC) — 17KB
- headera.jpg (GRAPHIC) — 12KB
- logoa.jpg (GRAPHIC) — 67KB
- 0001425450-24-000010.txt ( ) — 535KB
- kids-20240306.xsd (EX-101.SCH) — 2KB
- kids-20240306_def.xml (EX-101.DEF) — 3KB
- kids-20240306_lab.xml (EX-101.LAB) — 24KB
- kids-20240306_pre.xml (EX-101.PRE) — 15KB
- kids-20240306_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On March 6, 2024, OrthoPediatrics Corp. issued a press release announcing its earnings for the quarter and year ended December 31, 2023 and making other disclosures. The press release (including the accompanying unaudited condensed consolidated financial statements as of and for the quarter and year ended December 31, 2023, and other financial data) is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02, including the information incorporated by reference herein from Exhibit 99.1, is furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated March 6, 202 4 issued by OrthoPediatrics Corp. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * * * * * * SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OrthoPediatrics Corp. Date: March 6, 2024 By: /s/ Daniel J. Gerritzen Daniel J. Gerritzen, General Counsel and Secretary - 2 -